Hi

Earlier I started this but now is in Archive. https://forum.hegnar.no/archive/thread/2435820/view

we will continue the discussion here:

If we assume that AstraZeneca is our top 10 big pharma within FimaNAc collaboration, then the following might be of interest.

First look at page 24 from Pci Biotech June 2018 presentation. The page has a table with the Nucleic acids successfully delivered by fimaNAC, pay particular attention to the last nucleic acid "AAV vector" (Link: http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf)

on 10/07/2018 AstraZeneca and 4D MOLECULAR THERAPEUTICS announced the following:

https://www.4dmoleculartherapeutics.com/medimmune-and-4d-molecular-therapeutics-collaborate-to-design-develop-and-commercialize-aav-gene-therapy-for-chronic-lung-disease/

if we read the message carefully,

“The collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science.”

It seems this will start in clinical stages, meaning pre-clinical collaboration is over, is it a coincidence that our FimaNAc collaboration was extended a month earlier?. is it easy to assume that we are in collaboration with AstraZeneca where FimaNAc will be the mean of delivery for the AAV nucleic Acid? May be ! :)